Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes

Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up

“…Automation of insulin delivery systems has resulted in marked improvements in glycemic control with reductions in glycemic variability and prevention of SHEs. These technological advancements may help in reducing mortality associated with chronic hyperglycemic exposure and SHEs in T1D ( 5 ). However, it remains to be seen whether automated subcutaneous insulin delivery will result in better long-term survival as compared with restoration of endogenous insulin production in patients with T1D.…”

Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation

“…The constrained organ supply means that transplantation will never be able to address the huge burden of complications in type 1 diabetes. However, advances in biology (stem cell derived beta cells) and technology (automated insulin delivery systems "artificial pancreas") may enable people with diabetes to achieve a functional cure [98] which cannot come soon enough for people living with type 1 diabetes.…”

Errors of commission or omission: The net risk safety analysis conversation we should be having around automated insulin delivery systems

“…The same discussion of safety should be applied to both open source and commercial automated insulin delivery systems. In both cases, the discussion of safety by some healthcare providers and also by regulators may include an overestimation of risks 1 and may be anchored on a comparison to the risk to a person without diabetes, overlooking the daily and ongoing danger of living with insulin‐requiring diabetes. Instead, I propose that a net risk safety perspective should be used, considering the almost constant risk of insulin management for people living with diabetes 2 …”